Trial ID or NCT#

NCT01089101

Status

RECRUITING

Purpose

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Eligibility Criteria

Ages Eligible for Study: 3 Years to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michelle Monje
Neuro-oncologist
Associate Professor of Neurology and, by courtesy, of Neurosurgery, of Pediatrics, of Pathology and of Psychiatry and Behavioral Sciences
Sonia Partap
Paul Graham Fisher, MD
Neuro-oncologist, Pediatric neurologist
Bing Director of the Program in Human Biology, Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Health Research and Policy (Epidemiology) at SUMC

Contact us to find out if this trial is right for you.

CONTACT

Leah White
(650) 725-4708